Patients are critical in helping to transform optimism into reality by Ken Kahtava, Chief Business Officer, FSHD Society Breakthroughs in FSHD research have identified the primary mechanism that causes FSHD…. Read More »
(Cautious) optimism in FSHD drug development
Stay warm and safe
Our monthly Wellness Hour invited Dr. Mark Tarnopolsky of McMaster University to discuss an issue that many with FSHD face in winter: feeling especially susceptible to cold temperatures. He explains… Read More »
Teaching future doctors about FSHD
If we want to control the narrative, we need to tell our stories by Brian Jude Loiacono I was formally diagnosed with FSHD in January 2019. At that time I… Read More »
Promising findings from Avidity’s myotonic dystrophy trial
A major breakthrough for the field of RNA therapeutics Avidity Biosciences announced today that its investigational treatment for myotonic dystrophy type 1 (DM1), called AOC 1001, can be delivered into… Read More »
Springboards to the future
Everything we do propels us faster toward treatments and a cure We often speak of “filling potholes” and “overcoming obstacles” toward treatments and cures, but what the FSHD Society has… Read More »